+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID06614322

Sensory Testing to Predict Response to Pain Treatments in Peripheral Neuropathy A Randomized Double-Blind Crossover Trial Comparing Pregabalin, Duloxetine, and Placebo

Led by University of Rochester · Updated on 2026-09-16

190

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether quantitative sensory testing QST can classify individuals with painful peripheral neuropathy into different pain sub-groups and predict their response to pain treatments. This randomized, double-blinded, phase 2 trial compares three treatmentspregabalin, duloxetine, and a placeboover 19 weeks to assess their pain-relieving effects using measures like pain intensity and the Patient Global Impression of Change PGIC. Participants will receive each of the three treatments in a randomized sequence across three periods. Pregabalin is given as a 300mgday capsule, duloxetine as a 60mgday capsule, and placebo capsules are also used. Each treatment period lasts four weeks, and participants will be assigned to one of six possible sequences to receive these drugs. The study uses a crossover design allowing each participant to experience all treatments. During the trial, participants will undergo a QST exam, provide blood samples, complete computer-based questionnaires, and take study medications as instructed. Researchers will monitor pain intensity and PGIC from enrollment through each treatment period. The total participation time covers all three treatment periods and associated assessments, providing comprehensive data on treatment response in painful peripheral neuropathy.

CONDITIONS

Brief Title

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

Research Team

R

Rachel De Guzman

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here